Key result
This review summarizes the results of dose-finding studies and ongoing clinical trials for indirect and direct oral inhibitors of factor Xa and IIa in the prevention and treatment of venous thromboembolism.
Answers are grounded in this paper and cite their sources.
This review summarizes the clinical development and dose-finding studies of novel oral anticoagulants (Factor Xa and IIa inhibitors) for the prevention and treatment of venous thromboembolism.
Indirect systemic and direct oral factor Xa and direct oral factor IIa inhibitors with improved pharmacologic profiles compared with heparins and vitamin K antagonists are currently in clinical development. This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran). Specifically, the results of dose-finding studies for the prevention of venous thromboembolism after elective orthopedic surgery, the results of dose-finding studies for treatment of acute venous thromboembolism including prolonged prophylaxis of recurrent events, and the designs of ongoing clinical trials are reviewed.
No takes yet. Share an insight, caveat, or question.
Harenberg et al. (2008) conducted a review in Venous thromboembolism. Inhibitors of Factor Xa and Factor IIa (idraparinux, rivaroxaban, apixaban, dabigatran) was evaluated. This review summarizes the results of dose-finding studies and ongoing clinical trials for indirect and direct oral inhibitors of factor Xa and IIa in the prevention and treatment of venous thromboembolism.
Synapse has enriched 10 related papers. Consider them for comparative context: